Ahead of 2-day ad­comm, FDA sounds pos­i­tive on one blue­bird gene ther­a­py but ques­tions re­main for an­oth­er

4 years ago
Cell/Gene Tx
FDA+

Pas­cal So­ri­ot would­n't 'do any­thing dif­fer­ent­ly' in Covid-19 vac­cine de­vel­op­ment — re­port

4 years ago
People
Coronavirus

Gene ther­a­py biotech look­ing to by­pass vi­ral de­liv­ery wins in­vestor ap­proval, bag­ging Se­ries A

4 years ago
Financing
Startups

Bear mar­ket hits an­oth­er small cap biotech as Ahmed Hamdy's Vin­cerx cuts a third of staff

4 years ago
People

FDA slams small phar­ma for mis­lead­ing ad with a dearth of safe­ty in­fo and du­bi­ous stat cal­cu­la­tions

4 years ago
FDA+
Marketing

#AS­CO22: Min­gling face-to-face stole the spot­light in re­union with '50,000 of your clos­est friend­s'

4 years ago
People

No­var­tis is lat­est vic­tim of cy­ber­at­tack, but claims no con­fi­den­tial da­ta com­pro­mised — re­port

4 years ago
Pharma

Ab­b­Vie un­veils di­ver­si­ty, cli­mate and ac­ces­si­bil­i­ty strate­gies in new re­port

4 years ago
Pharma

DC ap­peals court quash­es Nos­trum's suit against FDA, ex­plain­ing CRLs are not fi­nal re­jec­tions

4 years ago
R&D
FDA+

Re­silience forges JV with MD An­der­son, ready­ing new cell ther­a­pies for can­cer

4 years ago
Pharma
Manufacturing

Bris­tol My­ers pulls plug on Re­blozyl pro­gram for rare blood dis­or­der, months af­ter missed PDU­FA date

4 years ago
Pharma
FDA+

#AS­CO22: Play­ing catch-up with Lumakras: Mi­rati touts CNS-spe­cif­ic ac­tiv­i­ty that an­a­lysts think pad the case for ...

4 years ago
R&D

Up­dat­ed: Trou­bled Emer­gent claims J&J will owe up to $420M if it pulls the plug on its Covid-19 vac­cine

4 years ago
Coronavirus
Manufacturing

Pfiz­er pumps $120M in­vest­ment in­to Kala­ma­zoo plant for Paxlovid pro­duc­tion

4 years ago
Pharma
Manufacturing

FDA shines light on In­di­an man­u­fac­tur­er’s mis­giv­ings at one of its fa­cil­i­ties

4 years ago
Pharma
FDA+

#AS­CO22: Ear­ly stock win­ner Adicet re­ports CRs for their off-the-shelf gam­ma delta CAR-T

4 years ago
R&D

#AS­CO22: A small Chi­na biotech play­er makes its de­but at AS­CO with promis­ing da­ta on its GPRC5D mul­ti­ple myelo­ma drug

4 years ago
Bioregnum
China

Fol­low­ing Vounatsos' an­nounced de­par­ture, Bio­gen part­ners with pri­vate Cana­di­an biotech for oral Parkin­son's ...

4 years ago
Deals

Prax­is nose­dives as an­ti­de­pres­sant ef­fort col­laps­es in PhII/III fail — lay­offs to fol­low

4 years ago
R&D

Amarin CFO re­signs amid cost-cut­ting mea­sures, staff re­duc­tion of 40%

4 years ago
People
R&D

Fol­low­ing deep cuts, Yu­man­i­ty strikes a deal to sell drugs to J&J, hands the keys to Genen­tech-part­nered Kine­ta

4 years ago
People
Deals

No hu­mans al­lowed: Alex Zha­voronkov adds ro­bot­ic lab to his AI drug dis­cov­ery play as In­sil­i­co un­veils $60M raise

4 years ago
Financing
AI

#AS­CO22: As it dodges a takeover bid, Zymeworks wants what Dai­ichi Sankyo got: a mas­sive Big Phar­ma part­ner

4 years ago
R&D

#AS­CO2022 roundup: CG On­col­o­gy builds on head-turn­ing com­bo da­ta; EQRx doesn’t have a way in­to US mar­kets

4 years ago
R&D
First page Previous page 518519520521522523524 Next page Last page
A service from the Financial Times